You are here

Targeting DNA damage response pathways for the treatment of advanced lung cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41ES025596-01A1
Agency Tracking Number: R41ES025596
Amount: $224,910.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIEHS
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2525 WEST END AVE, STE 950
NASHVILLE, TN 37203-1608
United States
DUNS: 69532880
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (615) 322-3606
Business Contact
Phone: (615) 255-0068
Research Institution
NASHVILLE, TN 37212-2809
United States

 () -
 Nonprofit college or university

DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced stage III cancer. For these patients chemo/radiation therapy remains the standard of care, and presently there isno effective strategy to improve radiation therapy outcomes. The central innovative theme of the proposed research is: a newly identified chemical entity YTR107 sensitizes human tumor cells to the lethal effects of ionizing radiation. YTR107 is efficacious in genetically diverse tumor types because its novel intracellular target plays a key role in homologous recombination, a critical DNA repair pathway utilized by dividing cells, including proliferative tumor cells. Targeting a key component of the DN

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government